Search

Displaying results 3511 - 3520 of 7607 in total
  1. Drug

    Dolasetron

    go.drugbank.com/drugs/DB00757
    ApprovedInvestigational

    This drug is not shown to have activity at other known serotonin receptors, and has low affinity for dopamine receptors.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Equine Botulinum Neurotoxin A Immune FAB2

    go.drugbank.com/drugs/DB13900
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A in adults and pediatric patients.

  3. Drug

    Tengonermin

    go.drugbank.com/drugs/DB16689
    Investigational

    [L33050] This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration. … [A233270] Literature demonstrates that NGR-peptides bind to a CD13 isoform, of which expression is restricted to tumor vasculature cells.

  4. Drug

    MK-1496

    go.drugbank.com/drugs/DB12763
    Investigational

    MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.

  5. Drug

    MK-5108

    go.drugbank.com/drugs/DB12556
    Investigational

    MK-5108 has been used in trials studying the treatment of Cancer, Neoplasms, Tumors.

  6. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients.

  7. Drug

    Technetium Tc-99m pyrophosphate

    go.drugbank.com/drugs/DB09165
    Approved

    A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process.

  8. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  9. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  10. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)